Successful Treatment of Primary CNS Extranodal NK/T-Cell Lymphoma with Surgery and Chemotherapy Combined with Sintilimab: A Case Report and Literature Review

References

• Grommes C, DeAngelis LM. Primary CNS lymphoma. J Clin Oncol. 2017;35(21):2410–2418. doi:10.1200/jco.2017.72.7602
   PubMed Web of Science ®Google Scholar
• Biccler JL, Savage KJ, Brown PDN, et al. Risk of death, relapse or progression, and loss of life expectancy at different progression-free survival milestones in primary central nervous system lymphoma. Leuk Lymphoma. 2019;60(10):2516–2523. doi:10.1080/10428194.2019.1594219
   PubMed Web of Science ®Google Scholar
• Le M, Garcilazo Y, Ibanez-Julia MJ, et al. Pretreatment hemoglobin as an independent prognostic factor in primary central nervous system lymphomas. Oncologist. 2019;24(9):e898–e904. doi:10.1634/theoncologist.2018-0629
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–2390. doi:10.1182/blood-2016-01-643569
   PubMed Web of Science ®Google Scholar
• Harabuchi Y, Takahara M, Kishibe K, Nagato T, Kumai T. Extranodal natural killer/T-cell lymphoma, nasal type: basic science and clinical progress. Front Pediatr. 2019;7:141. doi:10.3389/fped.2019.00141
   PubMed Web of Science ®Google Scholar
• Morita M, Osawa M, Naruse H, Nakamura H. Primary NK/T-cell lymphoma of the cauda equina: a case report and literature review. Spine. 2009;34(24):E882–E885. doi:10.1097/BRS.0b013e3181b29de6
   PubMedGoogle Scholar
• Cai B, Hu JJ, Tang QX, Lin W, Wang N. Primary meningeal NK/T cell lymphoma masquerading as tuberculous meningitis. Neurol Sci. 2014;35(9):1467–1469. doi:10.1007/s10072-014-1783-8
   PubMed Web of Science ®Google Scholar
• Imai A, Takase H, Imadome KI, et al. Development of extranodal NK/T-cell lymphoma nasal type in cerebrum following Epstein-Barr virus-positive uveitis. Intern Med. 2017;56(11):1409–1414. doi:10.2169/internalmedicine.56.7573
   PubMed Web of Science ®Google Scholar
• Cobo F, Talavera P, Busquier H, Concha A. CNK/T-cell brain lymphoma associated with Epstein-Barr virus in a patient with AIDS. Neuropathology. 2007;27(4):396–402. doi:10.1111/j.1440-1789.2007.00784.x
   PubMed Web of Science ®Google Scholar
• Kaluza V, Rao DS, Said JW, de Vos S. Primary extranodal nasal-type natural killer/T-cell lymphoma of the brain: a case report. Hum Pathol. 2006;37(6):769–772. doi:10.1016/j.humpath.2006.01.032
   PubMed Web of Science ®Google Scholar
• Liao B, Kamiya-Matsuoka C, Gong Y, Chen M, Wolf BA, Fowler NH. Primary natural killer/T-cell lymphoma presenting as leptomeningeal disease. J Neurol Sci. 2014;343(1–2):46–50. doi:10.1016/j.jns.2014.05.015
   PubMed Web of Science ®Google Scholar
• Li LF, Taw BB, Pu JK, Hwang GY, Lui WM, Leung GK. Primary central nervous system natural killer cell lymphoma in a Chinese woman with atypical (11)C-choline positron emission tomography and magnetic resonance spectrometry findings. World Neurosurg. 2015;84(4):1176 e1175–1179. doi:10.1016/j.wneu.2015.06.063
   Web of Science ®Google Scholar
• Yan J, Liu W, Wang X, et al. Primary central nervous system extranodal natural killer/T-cell lymphoma, nasal type colliding with meningioma. World Neurosurg. 2018;120:17–26. doi:10.1016/j.wneu.2018.08.065
   PubMed Web of Science ®Google Scholar
• Liu JK, Sayama C, Chin SS, Couldwell WT. Extranodal NK/T-cell lymphoma presenting as a pituitary mass. Case report and review of the literature. J Neurosurg. 2007;107(3):660–665. doi:10.3171/JNS-07/09/0660
   PubMed Web of Science ®Google Scholar
• Ng SB, Lai KW, Murugaya S, et al. Nasal-type extranodal natural killer/T-cell lymphomas: a clinicopathologic and genotypic study of 42 cases in Singapore. Mod Pathol. 2004;17(9):1097–1107. doi:10.1038/modpathol.3800157
   PubMed Web of Science ®Google Scholar
• Ogura R, Aoki H, Natsumeda M, et al. Epstein-Barr virus-associated primary central nervous system cytotoxic T-cell lymphoma. Neuropathology. 2013;33(4):436–441. doi:10.1111/neup.12005
   PubMed Web of Science ®Google Scholar
• Li D, Fu F, Lian L. Primary central nervous system extranodal nasal-type natural killer/T-cell lymphoma with CD20 expression. Neuropathology. 2018;38(2):198–204. doi:10.1111/neup.12438
   PubMed Web of Science ®Google Scholar
• Guan H, Huang Y, Wen W, Xu M, Zan Q, Zhang Z. Primary central nervous system extranodal NK/T-cell lymphoma, nasal type: case report and review of the literature. J Neurooncol. 2011;103(2):387–391. doi:10.1007/s11060-010-0384-5
   PubMed Web of Science ®Google Scholar
• Prajapati HJ, Vincentelli C, Hwang SN, Voloschin A, Crocker I, Dehkharghani S. Primary CNS natural killer/T-cell lymphoma of the nasal type presenting in a woman: case report and review of the literature. J Clin Oncol. 2014;32(8):e26–e29. doi:10.1200/JCO.2012.47.6796
   PubMed Web of Science ®Google Scholar
• Okada A, Harada Y, Inoue T, Okikawa Y, Ichinohe T, Kiuchi Y. A case of primary extranodal natural killer/T-cell lymphoma in the orbit and intraocular tissues with cerebrospinal fluid involvement. Am J Ophthalmol Case Rep. 2018;11:37–40. doi:10.1016/j.ajoc.2018.05.002
   PubMedGoogle Scholar
• Jiang X, Yin W, Song J, Chen X, Zhao C, Wen F. Primary central nervous system extranodal NK/T cell lymphoma, nasal type, with antecedent hemophagocytic syndrome in a child. Pediatr Dev Pathol. 2014;17(6):482–486. doi:10.2350/14-02-1441-CR.1
   PubMed Web of Science ®Google Scholar
• Shimatani Y, Nakano Y, Tsuyama N, et al. Extranodal NK/T-cell lymphoma, nasal type, manifesting as rapidly progressive dementia without any mass or enhancing brain lesion. Neuropathology. 2016;36(5):456–463. doi:10.1111/neup.12285
   PubMed Web of Science ®Google Scholar
• Miyata-Takata T, Takata K, Kato S, et al. Clinicopathological analysis of primary central nervous system NK/T cell lymphoma: rare and localized aggressive tumour among extranasal NK/T cell tumours. Histopathology. 2017;71(2):287–295. doi:10.1111/his.13223
   PubMed Web of Science ®Google Scholar
• Li X, Yu H, Fu X, et al. Clinical analysis of patients with primary and secondary extranodal natural killer/T-cell lymphoma of central nervous system. Hematol Oncol. 2021. doi:10.1002/hon.2894
   Web of Science ®Google Scholar
• Sabattini E, Bisgaard K, Ascani S, et al. The EnVision++ system: a new immunohistochemical method for diagnostics and research. Critical comparison with the APAAP, ChemMate, CSA, LABC, and SABC techniques. J Clin Pathol. 1998;51(7):506–511. doi:10.1136/jcp.51.7.506
   PubMed Web of Science ®Google Scholar
• Villano JL, Koshy M, Shaikh H, Dolecek TA, McCarthy BJ. Age, gender, and racial differences in incidence and survival in primary CNS lymphoma. Br J Cancer. 2011;105(9):1414–1418. doi:10.1038/bjc.2011.357
   PubMed Web of Science ®Google Scholar
• Allen PB, Lechowicz MJ. Management of NK/T-cell lymphoma, nasal type. J Oncol Pract. 2019;15(10):513–520. doi:10.1200/jop.18.00719
   PubMed Web of Science ®Google Scholar
• Hong M, Lee T, Young Kang S, Kim SJ, Kim W, Ko YH. Nasal-type NK/T-cell lymphomas are more frequently T rather than NK lineage based on T-cell receptor gene, RNA, and protein studies: lineage does not predict clinical behavior. Mod Pathol. 2016;29(5):430–443. doi:10.1038/modpathol.2016.47
   PubMed Web of Science ®Google Scholar
• Yang H, Xun Y, Yang A, Liu F, You H. Advances and challenges in the treatment of primary central nervous system lymphoma. J Cell Physiol. 2020;235(12):9143–9165. doi:10.1002/jcp.29790
   PubMed Web of Science ®Google Scholar
• Jo JC, Kim M, Choi Y, et al. Expression of programmed cell death 1 and programmed cell death ligand 1 in extranodal NK/ T-cell lymphoma, nasal type. Ann Hematol. 2017;96(1):25–31. doi:10.1007/s00277-016-2818-4
   PubMed Web of Science ®Google Scholar
• Kim WY, Jung HY, Nam SJ, et al. Expression of programmed cell death ligand 1 (PD-L1) in advanced stage EBV-associated extranodal NK/T cell lymphoma is associated with better prognosis. Virchows Arch. 2016;469(5):581–590. doi:10.1007/s00428-016-2011-0
   PubMed Web of Science ®Google Scholar
• Panjwani PK, Charu V, DeLisser M, Molina-Kirsch H, Natkunam Y, Zhao S. Programmed death-1 ligands PD-L1 and PD-L2 show distinctive and restricted patterns of expression in lymphoma subtypes. Hum Pathol. 2018;71:91–99. doi:10.1016/j.humpath.2017.10.029
   PubMed Web of Science ®Google Scholar
• Kwong YL, Chan TSY, Tan D, et al. PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase. Blood. 2017;129(17):2437–2442. doi:10.1182/blood-2016-12-756841
   PubMed Web of Science ®Google Scholar
• Lai J, Xu P, Jiang X, Zhou S, Liu A. Successful treatment with anti-programmed-death-1 antibody in a relapsed natural killer/T-cell lymphoma patient with multi-line resistance: a case report. BMC Cancer. 2017;17(1):507. doi:10.1186/s12885-017-3501-4
   PubMed Web of Science ®Google Scholar
• Li X, Cheng Y, Zhang M, et al. Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma. J Hematol Oncol. 2018;11(1):15. doi:10.1186/s13045-018-0559-7
   PubMed Web of Science ®Google Scholar
• Chan TSY, Li J, Loong F, Khong P-L, Tse E, Kwong Y-L. PD1 blockade with low-dose nivolumab in NK/T cell lymphoma failing L-asparaginase: efficacy and safety. Ann Hematol. 2018;97(1):193–196. doi:10.1007/s00277-017-3127-2
   PubMed Web of Science ®Google Scholar
• Nayak L, Iwamoto FM, LaCasce A, et al. PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma. Blood. 2017;129(23):3071–3073. doi:10.1182/blood-2017-01-764209
   PubMed Web of Science ®Google Scholar
• Lim JQ, Huang D, Tang T, et al. Whole-genome sequencing identifies responders to Pembrolizumab in relapse/refractory natural-killer/T cell lymphoma. Leukemia. 2020;34(12):3413–3419. doi:10.1038/s41375-020-1000-0
   PubMed Web of Science ®Google Scholar